alex

Thread about the unicorn of the OTC $ACMB From the ACMB website, there is a link to 'Starlink Securities' ACMB website: acmbcorp.weebly.com Starlink Securities: starlinksecurities.com.tw Starlink six major divisions: - Underwriting Division - Proprietary Trading & Investment Division - USD Asset Trust Division - Asset Management Division - Securities Advisory Division - Real World Asset Underwriting Division Pay attention to the co-founders. You will get very familiar with them.

@JolTrades Below is some of the $ACMB team with Kangli CEO and founder Mr. Li Shiqian front and center

$ACMB nice close. This time around is the float is locked by the ACMB OGs on here that are holding for the NASDAQ listing. Watch how little volume it takes to get above 10 cents this time. It’ll be volatile too because of how thin it is. Not for the faint of heart Check my two huge threads this weekend. My pinned tweet which has a link to the video thread

@TVestor3 Check 4th pic below. Will take you half a day to go through my stuff First pic from the CFO own mouth “As of February 2, 2026 its market capitalization ($ACMB) totaled US$45M However, once it reaches the United States, its valuation will be multiplied by at least 300 times”

$ACMB i need to dig into this this weekend if thats true then this is the easiest buy ever

For anyone new to $ACMB go through this thread and my pinned tweet They are currently selling shares to investors abroad at $1-2 per share I’m pretty sure the $1 round is closed. NASDAQ uplist is the plan. It’s a load up and hold. The company does not care about the OTC they believe it’s a gift you get to buy. Don’t expect any PR (they PR regularly in Taiwan)

Someone dumps everytime I tweet 😅 where did all the people that were pumping this go

$ACMB finally looks like an objectively good buy

$ACMB Q1 2026 quarterly report now filed on OTC Markets for period ending March 31, 2026 • 200,000,000 share patent acquisition completed with Twin Ox Holdings • AI, biotech, precision medicine & tokenization strategy now officially written into filings • Nasdaq uplist ambitions now formally stated in OTC Markets disclosure • Shareholder equity flipped from negative at Dec 2025 to +$3.76M by Mar 2026 • Filing repeatedly references acquisition activity and IP positioning Link: otcmarkets.com/file/company/f…

@fiddlebom They dump into stronger hands we know what is coming just not when

@datalifter I keep slapping when they keep dumping

$ACMB let this last impatient whale get out then we can move back up I think they’re expecting these Taiwan PRs to impact price. We accumulate for OTCM PR if it comes if not direct uplisting. They’re only posting on Chinese ACMB site for a reason they only want believers holding

Really good news coming out of $ACMB not expecting any positive market reaction out of it but they are clearly building a moat with their IP They also mentioned signing an MOU with this subsidiary of Mitsubishi: foodlink.co.jp/e/company/

It's worth noting that $ACMB has devised an innovative business model to optimize and enhance the company's asset value. In addition to providing CDMO services to global brands through OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer), ACMB plans to introduce STO (Security Token Offering). By digitizing its "Hamahiga Island Contractual Farm Base" and "patented technologies," ACMB will be able to effectively strengthen its operational momentum, allowing global investors to directly participate in the growth opportunities of the longevity economy. Furthermore, ACMB will launch a highly efficient M&A strategy targeting the Asian, American, and European markets to continuously expand its market share. Deepening Implementation: Japanese Expert Team Returns Visit to Kaohsiung As the cooperation accelerates, a team of experts from Japan's Ryukyu Health Foods Co., Ltd. will visit Taiwan this week in return, personally inspecting ACMB's headquarters and burdock production base in Kaohsiung, Taiwan, and touring the Siaogang Food Factory. The Japanese team's trip aims to verify ACMB's automated processes and sterilization technology, ensuring that exported products meet international pharmacopoeia-level standards. ACMB Chairperson Yu-Chia Chou emphasized, "We are not just selling products; we are building an international biomedical industry moat." When Asia's top-quality materials meet American capital and Taiwan's R&D, ACMB will redefine the international standards of the global longevity industry.

$ACMB partners with Okinawa's brown algae giant! Patented burdock and premium brown algae launch a new highlight in the global longevity economy. With the trend of a super-aged society, the longevity economy has become a new global highlight. ACMB (Agro Capital Management Corp., OTC: ACMB), a US-listed biotechnology holding company, announced that it has successfully reached a cross-border strategic alliance with a leading biotechnology industry in Okinawa, Japan. This powerful alliance spanning three regions not only incorporates the top-quality brown algae resources of Hamahiga Island in Okinawa into its R&D portfolio, but also combines ACMB's core burdock patent technology, marking the beginning of a new era of "vertical integration" in the global longevity biomedical industry. Strategic Alignment: The Profound Value of Brown Algae on Hamahiga Island ACMB sent a delegation to Okinawa, Japan for an on-site inspection, and reached a cooperation agreement with Ryukyu Health Food Co., Ltd., signing a Memorandum of Understanding (MOU). (ACMB/Provided) From May 2nd to 5th, ACMB organized a delegation to Okinawa, Japan, led by Director Chiu Jui-tang and including the board of directors and core shareholders, to conduct an on-site inspection. The delegation visited Hamahiga Island, known as a longevity paradise, where the surrounding waters boast exceptionally pure ocean currents, producing "Haiyun" seaweed with a fucoidan content more than three times higher than that of ordinary seaweed. During the visit, ACMB reached a deep cooperation agreement with two Japanese biotech giants—Foods Link, representative director Masaharu Kina, and Ryukyu Healthy Foods, representative director Kazumasa Horyo—and signed a Memorandum of Understanding (MOU). The two parties established mutual agency rights for multiple products, officially forming an alliance between Okinawa's "longevity IP" and the US stock market capital platform. ACMB Chairperson Chou Yu-Chia (left) and Ryukyu Health Food Co., Ltd. Representative Director Yasuyoshi Kazumasa (right) jointly signed a Memorandum of Understanding (MOU), signifying their intention to further deepen their cooperation. (Provided by ACMB) Technological Synergy: Four Major Burdock Patents X Top-Grade Brown Algae ACMB CEO Lan Zihong stated that the core of this collaboration lies in integrating ACMB's four core burdock-based patented technologies with Okinawa brown algae for bioactivity. Through low-temperature extraction and molecular fragmentation technologies, the two parties will launch three core projects targeting the global market: high-end health foods, functional food additives, and anti-cancer drug development. Utilizing the synergistic effect of fucoidan and burdock extract, they will advance precision medicine research. ACMB has reached a transnational collaboration with a leading biotechnology industry in Okinawa, Japan, incorporating the top-quality brown algae resources of Hamahiga Island in Okinawa into its research and development. (ACMB/Provided)

Thread about the unicorn of the OTC $ACMB From the ACMB website, there is a link to 'Starlink Securities' ACMB website: acmbcorp.weebly.com Starlink Securities: starlinksecurities.com.tw Starlink six major divisions: - Underwriting Division - Proprietary Trading & Investment Division - USD Asset Trust Division - Asset Management Division - Securities Advisory Division - Real World Asset Underwriting Division Pay attention to the co-founders. You will get very familiar with them.

@JolTrades 30. $ACMB translated audio and slides from two months ago with some details regarding their Series C funding round and share buyback plan where shares were sold for $1 USD each, plus a varying amount of tokenized Antrodia Cinnamomea depending on total commitment of USD invested

29. $ACMB translated video and slides about new partnership with Japanese cultivator of rare Okinawa Mozuku longevity seaweed that they plan to CDMO for drug development & manufacturing, tokenize on chain, and integrate with their technologies to sell products globally on Amazon and GNC

Thread about $ACMB. This could be one of the rarest plays in OTC with a clear plan to go Nasdaq, real-world biotech assets on blockchain, and an experienced team driving it. Translated videos from their Chinese marketing partner below. 🧵👇

I’ve been saying this is a year long hold since day one and haven’t sold a share only buying. Not expecting much until the company decides they are ready to bring this to the US and I wouldn’t be surprised if they skip the OTC phase altogether given the abysmal volume and weak hands

Bringing back up the two comprehensive DD threads with hours of content to absorb 1. Kangli Biotech reverse merger research and $ACMB core team background x.com/datalifter/sta… 2. Translated video thread x.com/datalifter/sta…